In the ARETHUSA trial (NCT03519412) the metastatic-colorectal patients who failed standard therapies undergo treatment with pembrolizumab, are tested for o6-methylguanine-DNA-methyltransferase (MGMT) expression (IHC), then for MGMT promoter methylation [43]. This evidence concerns the gene MGMT and medical procedure.